陳蘭美

男， 廣東醫(yī)科大學(xué)， 教授/研究員/教授級(jí)高工或同等級(jí)別

學(xué)習(xí)/工作經(jīng)歷

工作經(jīng)歷：
(1) 2020.01至現(xiàn)在, 廣東醫(yī)科大學(xué), 藥學(xué)院, 教授
(2) 2019-8至2020-8, Murdoch University, Centre for Molecular Medicine&Innovative Therapeutics, Visiting Fellow
(3) 2014.01至2020.03, 廣東醫(yī)科大學(xué), 藥學(xué)院, 副教授
(4) 2009.03至2013.12, 廣東醫(yī)科大學(xué), 藥學(xué)院, 講師
(5) 2008.07至2009.01, 廣東醫(yī)科大學(xué), 藥學(xué)院, 助教

學(xué)習(xí)教育經(jīng)歷：
(1) 2003.09 至 2008-07, 中山大學(xué), 化學(xué)生物學(xué), 博士（碩博聯(lián)讀）
(2) 1999-09 至 2003-07, 信陽師范大學(xué), 化學(xué)教育, 學(xué)士

研究領(lǐng)域和興趣

生物無機(jī)化學(xué)，藥物化學(xué)

主要業(yè)績(jī)

主要從事具有靶向功能的天然產(chǎn)物小分子及其金屬配合物的設(shè)計(jì)、合成及其抗腫瘤和抗菌研究。2015年廣東省高等院校優(yōu)秀青年教師培養(yǎng)對(duì)象，廣東省高等學(xué)?！扒О偈瞬排囵B(yǎng)工程”校級(jí)培養(yǎng)對(duì)象，廣東省自然科學(xué)基金評(píng)審專家及Journal of Medicinal Chemistry, Chemical Engineering Journal, Advanced Science, Theranostics，European Journal of Medicinal Chemistry等雜志審稿人。先后主持國家自然科學(xué)青年基金，廣東省自然科學(xué)基金，廣東省優(yōu)秀青年教師培養(yǎng)項(xiàng)目，廣東省衛(wèi)生廳及中藥局等課題。以第一或通訊作者在國際知名SCI期刊上發(fā)表高水平論文38篇，H-index: 31，其中近五年來發(fā)表18篇。申請(qǐng)國家發(fā)明專利11項(xiàng)，已授權(quán)9項(xiàng)。

代表成果

[1] Xufeng Zhu1, Jinjun Chen1, Binhua Wu, Yating Huang, Yan Zou, Chunmei Liang, Yingnian Lu*, Hui Luo, Lanmei Chen*, Jincan Chen*, Polyvalent copper oxide nanozymes: Co-delivery of ROS and NO for inducing cuproptosis-like bacterial death against MRSA infections, Chemical Engineering Journal, 2024, 499, 156507.
[2] Jincan Chen1, Qian Wu1, Shenting Zhang, Jie Gao, Wenzhu Yu, Tianling Hu, Jiale Zhu, Miao Guo, Xufeng Zhu*, Lanmei Chen*, The efficient screening of avermectin B1a aptamer and colorimetric detection of its regulation of Ru NPs activity, Microchemical Journal, 2024, 206, 111429.
[3] Xufeng Zhu1, Chunmei Liang1, Jinjun Chen, Jie Gao, Weigang Chen, Qianqian Ouyang, Lianxiang Luo, Zunnan Huang, Hui Luo, Lanmei Chen*, Jincan Chen*, Phase separation of extracellular polymeric substances induced by bacteria responsive Nano-Antibiotics for drug-resistant bacterial infection management, Chemical Engineering Journal, 2024, 481, 148136.
[4] Lanmei Chen, Hong Tang, Tianling Hu, Jie Wang, Qianqian Ouyang, Xufeng Zhu*,Rui Wang, Wenyong Huang, Zunnan Huang*, Jincan Chen*, Three Ru(II) complexes modulate the antioxidant transcription factor Nrf2 to overcome cisplatin resistance, Journal of Inorganic Biochemistry, 2024, 259, 112666.
[5] Xufeng Zhu#, Qiang Sun#, Xinhua Guo, Chunmei Liang, Yao Zhang, Wenyong Huang, Wenliang Pei, Zunnan Huang*, Lanmei Chen*, Jincan Chen*, Cyclometalated ruthenium (II) complexes induced HeLa cell apoptosis through intracellular reductive injury, Journal of Inorganic Biochemistry, 2023, 112333.
[6] Weigang Chen, Xianhong Cai, Qiang Sun, Xinhua Guo, Chunmei Liang, Hong Tang,3 Heming Huang, Hui Luo, Lanmei Chen*, Jincan Chen*, Design and synthesis of aptamer-cyclometalated iridium(III) complex conjugate targeting cancer cells, European Journal of Medicinal Chemistry, 2022, 236, 114335.
[7] Lanmei Chen, Jie Wang, Xianhong Cai, Suxiang Chen, Jingjing Zhang, Baojun Li, Weigang Chen, Xinhua Guo, Hui Luo*, Jincan Chen*, Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway, Bioorganic Chemistry, 2022, 119, 105516.
[8] Jincan Chen, Yuanyuan Deng, Jie Wang, Suxiang Chen, Fa Peng, Xuerong He, Meijun Liu, Hui Luo*, Jingjing Zhang*, Lanmei Chen*, Cyclometalated Ru(II) β-carboline complexes induce cell cycle arrest and apoptosis in human HeLa cervical cancer cells via suppressing ERK and Akt signaling, Journal of Biological Inorganic Chemistry, 2021, 26, 793–808.
[9] Tao Wang#, Lanmei Chen#, Arpitha Chikkanna, Suxiang Chen, Isabell Brusius, Nabayet Sbuh, Rakesh N. Veedu*, Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis, Theranostics, 2021, 11, 5174-5196
[10] 陳蘭美，陳錦燦，吳謙，朱旭峰，張沈婷，郭淼，一種阿維菌素B1a適配體及其篩選方法和應(yīng)用，中國，發(fā)明專利，專利號(hào)：ZL 2024 1 0158148.1，申請(qǐng)日：2024.02.04，授權(quán)日：2025.01.24。

*以上信息由高級(jí)會(huì)員個(gè)人更新和維護(hù)。